DrugDashboards

Relexxii

methylphenidate hydrochloride · METHYLPHENIDATE HYDROCHLORIDE 27 mg/1 · Tablet, Extended Release · Oral · Vertical Pharmaceuticals, LLC

NDC 68025-0096-10 · 100 TABLET, EXTENDED RELEASE in 1 BOTTLE · NDA · View full market →

The short version

12 companies supply this market — deep enough that no single failure threatens the supply. The brand price has held steady around $11.48 per unit over the past year. Generic versions run $0.6665 per unit — 19× cheaper. It is in shortage right now — FDA lists the reason as “demand increase for the drug”. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$11.48per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$15.64per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$12.37per unitnegotiated price across 6 plans — before rebates · Apr 1, 2026
  • Federal ceiling (Big4)$6.31per unitAvion Pharmaceuticals, LLC · Jan 1, 202655% of what pharmacies pay — a deeper discount than 86% of drugs with this benchmark
  • Medicaid generic ceiling (FUL)$2.13per TABweighted avg manufacturer price $1.2172 · Aug 1, 202619% of what pharmacies pay — a deeper discount than 95% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$12.37per unit
middle half $12.37–$12.37 · 6 plans · Apr 1, 2026
Est. net of rebatesⓘ
$7.42–$9.28
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
0%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 100%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$5.00$10.00$15.00Oct 2024Sep 2026$11.48
16 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$344.34
#90 count
$1033.01

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$11,587
38 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

25● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • in shortage now+25

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for methylphenidate hydrochloride (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA216117
TE code
—
Approval date
Jun 23, 2022
Patents / exclusivity
35 patents, 0 exclusivities
TypeNumber / codeExpires
patent10695336Feb 3, 2037
patent10695336Feb 3, 2037
patent10695336Feb 3, 2037
patent10695336Feb 3, 2037
patent10695336Feb 3, 2037
patent10695336Feb 3, 2037
patent10695336Feb 3, 2037
patent10265308Feb 3, 2037
patent10265308Feb 3, 2037
patent10265308Feb 3, 2037
patent10265308Feb 3, 2037
patent10265308Feb 3, 2037

Shortage history

  • In shortage now — Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)Jul 26, 2023
    Discontinuation of the manufacture of the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)Jul 26, 2023
    Discontinuation of the manufacture of the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)Jul 26, 2023
    Discontinuation of the manufacture of the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)Jul 26, 2023
    Discontinuation of the manufacture of the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)Jul 26, 2023
    Demand increase for the drug
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)Jul 26, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 31% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of methylphenidate hydrochloride (Tablet, Extended Release)

LabelerStrengthFirst seenLast seen
American Health PackagingMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingMETHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingMETHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Dr.Reddys Laboratories IncMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.METHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Granules Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Granules Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
Janssen Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Janssen Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Janssen Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Janssen Pharmaceuticals, Inc.METHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Northstar Rx LLCMETHYLPHENIDATE HYDROCHLORIDE 72 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 10 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
SpecGx LLCMETHYLPHENIDATE HYDROCHLORIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.METHYLPHENIDATE HYDROCHLORIDE 72 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 45 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 54 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 63 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 36 mg/1Jul 15, 2026Sep 2, 2026
Trigen Laboratories, LLCMETHYLPHENIDATE HYDROCHLORIDE 72 mg/1Jul 15, 2026Sep 2, 2026
Vertical Pharmaceuticals, LLCMETHYLPHENIDATE HYDROCHLORIDE 72 mg/1Jul 15, 2026Sep 2, 2026
Vertical Pharmaceuticals, LLCMETHYLPHENIDATE HYDROCHLORIDE 18 mg/1Jul 15, 2026Sep 2, 2026
Vertical Pharmaceuticals, LLCMETHYLPHENIDATE HYDROCHLORIDE 27 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Relexxii — NDC 68025-0096-10," retrieved September 3, 2026, https://drugdashboards.com/drug/68025009610.

Free to cite with attribution — see how the data is put together.